Table 4 Univariate and multivariate analyses of overall survival (N = 30)

Sex

Male

20

29.4

0.458

Female

10

22.6

1.44 (0.54–3.81)

Age

<69

14

29.4

0.569

≥69

16

22.6

1.30 (0.53–3.16)

Performance status

0–1

19

36.1

0.002

0.004

2–4

11

11.4

4.06 (1.58–10.43)

4.11 (1.57–10.76)

CEA (ng/ml)

<16.9

14

29.4

0.386

≥16.9

16

22.6

1.51 (0.59–0.82)

K-ras

Wild-type

12

17.4

0.051

Mutated

14

36.7

0.357 (0.12–1.05)

Stage

Relapse after surgery

15

36.7

0.453

IV

15

22.6

1.42 (0.56–3.59)

Respiratory diseases

No

19

22.6

0.875

Yes

11

29.4

0.93 (0.37–2.34)

MTB or MK infection

No

23

22.6

0.536

Yes

7

36.7

0.705 (0.23–2.15)

Primary site

Rectum

16

29.4

0.322

Colon

14

22.6

0.615 (0.23–1.62)

Number of metastatic organs

1

13

36.7

0.0893

≥2

17

16.9

2.2 (0.87–5.58)

Lung metastasis

No

12

16.9

0.483

Yes

18

29.4

0.72 (0.29–1.79)

Liver metastasis

No

17

36.1

0.020

0.030

Yes

13

11.9

3.24 (1.15–9.11)

3.37 (1.13–10.07)